Status
Completed
Phase
PHASE4
Study type
Interventional
Enrollment
600
Sex
Women only
Ages
Ages 20 Years to 40 Years
Primary completion
2024-07-15
Last update
2026-03-19

What this trial studies

The aim of this study is to test the hypothesis that addition of daily small dose of human menopausal gonadotropin (HMG) drug following oocytes retrieval could improve the fertility outcome in women undergoing in-vitro fertilization

Conditions in scope

  • Infertility

Interventions

  • human menopausal gonadotropin (Drug) — Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles

Who can join

Women only · Ages 20 Years to 40 Years

Inclusion criteria

  • Females undergoing Intra-Cytoplasmic Sperm Injection (ICSI) cycles
  • Age between 20 and 40 years

Exclusion criteria

  • Females who have high response (estradiol at time of ovulation trigger is \> 5000 pg/ml or more than 15 oocytes are retrieved)

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

CityState / RegionFacilitySite status
Cairo Greater Cairo Department of Obstetrics and Gynecology, Kasr Al-Ainy hospital Unknown

Status & timeline

  • Overall status: Completed
  • Study type: Interventional
  • Phase: PHASE4
  • Start date: 2017-07-06
  • Primary completion: 2024-07-15
  • Last update posted: 2026-03-19
  • First posted: 2017-07-06

Lead sponsor: Cairo University (Other)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

  • Live birth rate (This outcome will be calculated 2 years after enrollment of the first patient in the study)
    The live birth rate will be calculated by a statistician for each group

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.

Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT03209687 before contacting a site.

ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.